A number of other research firms have also recently weighed in on BLRX. Zacks Investment Research raised Bioline RX from a hold rating to a buy rating and set a $1.25 price objective for the company in a research report on Tuesday, October 3rd. HC Wainwright set a $4.00 price objective on Bioline RX and gave the stock a buy rating in a research report on Wednesday, August 9th. Roth Capital set a $3.00 price objective on Bioline RX and gave the stock a buy rating in a research report on Wednesday, August 9th. Maxim Group set a $3.00 price objective on Bioline RX and gave the stock a buy rating in a research report on Tuesday, August 8th. Finally, ValuEngine raised Bioline RX from a strong sell rating to a sell rating in a research report on Thursday, November 30th. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus target price of $2.88.
Bioline RX (NASDAQ:BLRX) traded up $0.01 during trading on Monday, hitting $1.09. The stock had a trading volume of 493,686 shares, compared to its average volume of 521,009. The firm has a market cap of $113.47, a PE ratio of -3.30 and a beta of 0.89. Bioline RX has a 52-week low of $0.80 and a 52-week high of $1.38.
About Bioline RX
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease.
Receive News & Ratings for Bioline RX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioline RX and related companies with MarketBeat.com's FREE daily email newsletter.